Regulation of signaling pathways by β-elemene in cancer progression and metastasis
© 2019 Wiley Periodicals, Inc..
Entry of β-elemene into various phases of clinical trials advocates its significance as a premium candidate likely to gain access to mainstream medicine. Based on the insights gleaned from decades of research, it seems increasingly transparent that β-elemene has shown significant ability to modulate multiple cell signaling pathways in different cancers. We partition this multicomponent review into how β-elemene strategically modulates various signal transduction cascades. We have individually summarized regulation of tumor necrosis factor related apoptosis-inducing ligand, signal transducers and activators of transcription, transforming growth factor/SMAD, NOTCH, and mammalian target of rapamycin pathways by β-elemene. Last, we will discuss the results of clinical trials of β-elemene and how effectively we can use these findings to stratify patients who can benefit most from β-elemene.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:120 |
|---|---|
| Enthalten in: |
Journal of cellular biochemistry - 120(2019), 8 vom: 10. Aug., Seite 12091-12100 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Qureshi, Muhammad Z [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Apoptosis |
|---|
| Anmerkungen: |
Date Completed 05.08.2020 Date Revised 05.08.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/jcb.28624 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM29534587X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM29534587X | ||
| 003 | DE-627 | ||
| 005 | 20231225083448.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jcb.28624 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0984.xml |
| 035 | |a (DE-627)NLM29534587X | ||
| 035 | |a (NLM)30912190 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Qureshi, Muhammad Z |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Regulation of signaling pathways by β-elemene in cancer progression and metastasis |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 05.08.2020 | ||
| 500 | |a Date Revised 05.08.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019 Wiley Periodicals, Inc. | ||
| 520 | |a Entry of β-elemene into various phases of clinical trials advocates its significance as a premium candidate likely to gain access to mainstream medicine. Based on the insights gleaned from decades of research, it seems increasingly transparent that β-elemene has shown significant ability to modulate multiple cell signaling pathways in different cancers. We partition this multicomponent review into how β-elemene strategically modulates various signal transduction cascades. We have individually summarized regulation of tumor necrosis factor related apoptosis-inducing ligand, signal transducers and activators of transcription, transforming growth factor/SMAD, NOTCH, and mammalian target of rapamycin pathways by β-elemene. Last, we will discuss the results of clinical trials of β-elemene and how effectively we can use these findings to stratify patients who can benefit most from β-elemene | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a apoptosis | |
| 650 | 4 | |a cancer | |
| 650 | 4 | |a elemene | |
| 650 | 4 | |a signaling | |
| 650 | 7 | |a Sesquiterpenes |2 NLM | |
| 650 | 7 | |a beta-elemene |2 NLM | |
| 700 | 1 | |a Attar, Rukset |e verfasserin |4 aut | |
| 700 | 1 | |a Romero, Mirna A |e verfasserin |4 aut | |
| 700 | 1 | |a Sabitaliyevich, Uteuliyev Y |e verfasserin |4 aut | |
| 700 | 1 | |a Nurmurzayevich, Sadykov B |e verfasserin |4 aut | |
| 700 | 1 | |a Ozturk, Ozlem |e verfasserin |4 aut | |
| 700 | 1 | |a Wakim, Lara H |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Xiukun |e verfasserin |4 aut | |
| 700 | 1 | |a Ozbey, Ulku |e verfasserin |4 aut | |
| 700 | 1 | |a Yelekenova, Armida Bakhytbekovna |e verfasserin |4 aut | |
| 700 | 1 | |a Farooqi, Ammad A |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of cellular biochemistry |d 1985 |g 120(2019), 8 vom: 10. Aug., Seite 12091-12100 |w (DE-627)NLM012621285 |x 1097-4644 |7 nnns |
| 773 | 1 | 8 | |g volume:120 |g year:2019 |g number:8 |g day:10 |g month:08 |g pages:12091-12100 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jcb.28624 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 120 |j 2019 |e 8 |b 10 |c 08 |h 12091-12100 | ||